PeptideGlobal

Indian generic semaglutide makers push into Canada Brazil and Africa as home prices slide

Dr Reddy's, Sun Pharma and Hetero already sell or ship generic semaglutide abroad, while Lupin, Biocon and Ajanta work through partners. Canada, Brazil and South Africa each pose a different test as the Indian market slows after its patent expiry rush.

Illustration for the story: Indian generic semaglutide makers push into Canada Brazil and Africa as home prices slide

Illustration by Peptide Global, not a picture of the place in the story.

The short of itIndian drugmakers led by Dr Reddy's, Sun Pharma and Hetero are taking generic semaglutide to Canada, Brazil, South Africa and dozens of other markets as the home market slows.

Indian generic semaglutide is moving abroad. Dr Reddy's, Sun Pharma and Hetero already sell or ship their copies of Novo Nordisk's diabetes and weight loss drug outside India, and Lupin, Biocon and Ajanta are lining up partners for dozens more countries, Business Standard reported on 18 November. The push comes as the home market, opened when the Indian patent expired in March, settles after a rush of launches, falling prices and heavy stocking by distributors.

Who is selling where

Dr Reddy's has gone furthest with Indian generic semaglutide. It launched in Canada earlier this year and this month won approval from Brazil's regulator ANVISA, with approvals reported in 10 countries in total. The company is aiming for six to seven million pens across 10 markets in the second half of its 2027 financial year, with Canada expected to take most of that volume. In Chile it was cleared as the first generic entrant, chief executive Erez Israeli has said. Canadian supply was interrupted, though, by a recall linked to an impurity above specification and a separate packaging and labelling error. Israeli told analysts in October that supply should resume in November once validation succeeds.

Sun Pharma launched its semaglutide in South Africa in July, and its local partner has started selling the product in Brazil, managing director Kirti Ganorkar confirmed on the October earnings call. He would not say how far prices have fallen, noting that the Brazilian partner sets them. Hetero has begun exporting to markets in Africa, Asia and the Middle East under three brand names and plans to reach more than 75 countries over time. Its manufacturing partner Gufic Biosciences said in August that the two firms had filed for approval in more than 22 countries. In November, Gufic said revenue from those registrations should start in the first or second quarter of the next financial year, provided the approvals arrive.

Partnerships for the next wave

Three more Indian companies are going abroad through partners rather than through their own filings. Lupin signed a licensing and supply agreement with Spain's Galenicum Health in January covering 23 countries, according to Lupin's announcement. Under that deal Galenicum develops, makes and supplies the finished injection, while Lupin handles regulatory filings and sales in territories that include Canada, Europe, Southeast Asia and Latin America. No financial terms were disclosed. Biocon has teamed up with Ajanta Pharma to supply semaglutide for sale in 26 countries across Africa, the Middle East and Central Asia. Ajanta does not expect commercial sales before its 2028 financial year, because it still has to work through regulatory reviews in those markets.

For Indian generic semaglutide, the overseas push looks less like a rescue for a crowded home market and more like the result of filings started well before the patent expired.

Business Standard noted that the move abroad is not simply a way to clear stock that built up in India. Several companies began work on foreign approvals and commercial partnerships long before the Indian patent ran out. For Indian generic semaglutide, the overseas push looks less like a rescue for a crowded home market and more like the result of filings started well before the patent expired. That matters for readers in importing countries, because it points to a steady pipeline of applications rather than a one-off release of surplus pens. It also means quality systems, stability data and pen supply will be examined by many regulators at once, as the recall in Canada has already shown.

Three markets with different rules

The target markets are not alike. Canada uses close to 12 million semaglutide injection pens a year, and its wider GLP-1 market is put at $2.6 billion, according to figures cited by Sandoz. Yet Novo Nordisk has held on to a large share there since protection ended in January, partly because generic launches were slow. Brazil's semaglutide market for diabetes is worth about $245 million, according to IQVIA data cited by Dr Reddy's, and cheaper versions are already taking share. Novo has said pricing pressure in Brazil helped push its emerging market sales down 3 percent in the September quarter, and Sandoz launched its own semaglutide injection in Brazil this month.

South Africa is the third test. Its GLP-1 market is approaching $182 million, according to Aspen Pharmacare figures, but tirzepatide makes up most of it, so semaglutide copies compete against a different leading drug. The national regulator had 12 generic semaglutide applications under review in July, and Aspen won approval for its own semaglutide injection this month. More entrants could widen access to lower priced versions, the paper said, while competition grows with each new product. For makers of Indian generic semaglutide, being first in a country may not stay an advantage for long, and approval timing will matter as much as the price they can offer to distributors and public buyers.

CompanyOverseas position reported
Dr Reddy'sLaunched in Canada, approved in Brazil and Chile, approvals in 10 countries
Sun PharmaLaunched in South Africa in July, sold in Brazil through a partner
HeteroExports under three brands, filings in more than 22 countries with Gufic
LupinGalenicum deal covering 23 countries
Biocon and AjantaSupply deal for 26 countries, sales expected from FY28

The home market they leave behind

At home, the data show a market growing in volume faster than in value. Monthly semaglutide volumes went from 1.14 lakh units in February to 4.34 lakh in September, according to Pharmarack's PharmaTrac figures cited by Business Standard, while sales value climbed from Rs 48 crore to Rs 113 crore. Generic brands made up about 74 percent of volumes in September. Growth has slowed since the first wave: volumes jumped 88 percent in April, then rose 12 percent in May and 4 percent in June, stayed roughly flat in August and grew 7 percent in September. This site reported last month that Eris Sundae semaglutide led Indian prescriptions but ranked second by value.

Distributors also stocked heavily. Channel inventory stood at 16 days in February, peaked at 26 days in May and was down to 23 days by August, with some brands holding much more. Nirali Shah of Ashika Investment Managers had told Business Standard that the market was shifting from a "buzz phase" to a "prescription habit phase". For Dr Reddy's, whose Canadian semaglutide restart hangs on validation batches, the coming weeks will show whether supply resumes on schedule. Across the group, the dates to watch are new approvals in Africa and Latin America, the first export revenue for Hetero and Gufic, and the start of sales by Ajanta in its 2028 financial year.

Conclusion

Indian generic semaglutide is now an export story as well as a domestic one, with three companies already selling abroad and three more working through partners. Canada, Brazil and South Africa each offer a different mix of demand, brand loyalty and rival copies. The signals to watch are the Dr Reddy's restart in Canada, approvals from the Hetero and Gufic filings in more than 22 countries, and whether the price erosion seen in India repeats abroad.

Why it matters in India

India became the first big generic semaglutide market after its patent expired in March. Volumes have quadrupled but prices fell and stocks built up, so Indian makers are using filings and partnerships abroad to reach markets where demand is already established.

What to watch

Whether Dr Reddy's resumes Canadian supply in November, new approvals from Hetero and Gufic filings in more than 22 countries, and Ajanta sales from its 2028 financial year.

Sources

  1. Business Standard: Indian drugmakers take generic semaglutide battle to overseas markets
  2. Lupin: Lupin and Galenicum sign license and supply agreement for semaglutide in 23 countries

Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.

Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.